Compare Citius Pharmaceuticals Inc (CTXR) vs Schwab US Dividend Equity ETF (SCHD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Schwab US Dividend Equity ETF — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while Schwab US Dividend Equity ETF trades at $33.04 (market cap $110.56B). The key difference: Schwab US Dividend Equity ETF is far larger — about 8117.5× Citius Pharmaceuticals Inc's market cap, and Schwab US Dividend Equity ETF is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and Schwab US Dividend Equity ETF for 62 Days on average.
| CTXR | SCHD | |
|---|---|---|
Market Cap | $13.62M | $110.56B |
Volume | 132,438 | 23,539,168 |
Sector | Health | Broad Market / Factor |
52-Week High | $1.82 | $35.21 |
52-Week Low | $0.48 | $26.44 |
Typical Hold Time | 17 Days | 62 Days |
Enterprise Value | $3.79M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
SCHD trades at $33.06, up 1.26% today, with a bullish technical signal despite mixed moving averages. The ETF has outperformed the S&P 500 in 2026, with recent news highlighting its dividend growth and defensive positioning. Key support sits at $32 with resistance at $34, while oscillators show neutral momentum. The fund's rules-based approach focuses on high-quality dividend stocks, though recent exclusions like Broadcom have sparked discussion about opportunity costs.
SCHD offers income investors exposure to rising dividends with lower fees, but faces headwinds from interest rate sensitivity and strict selection criteria that may limit growth participation. The current pullback from August highs near $35 presents a potential entry point for dividend-focused portfolios seeking quality and yield sustainability amid market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Schwab US Dividend Equity ETF
SCHD is an ETF that tracks the Dow Jones U.S. Dividend 100 Index. It selects high-quality companies with a consistent track record of paying dividends, focusing on financial strength metrics like cash flow to total debt and return on equity, and excluding REITs. The fund aims to provide both income and capital appreciation, making it a popular choice for long-term, dividend-focused investors.
Read more on SCHD →
